Ack1 Mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Mahajan, Kiran ^a   Coppola, Domenico ^a   Challa, Sridevi ^a   Fang, Bin ^a   Chen, Y Ann ^a   Zhu, Weiwei ^a   Lopez, Alexis S ^a   Koomen, John ^a   Engelman, Robert W ^a   Rivera, Charlene ^b   Muraoka Cook, Rebecca S ^b   Cheng, Jin Q ^a   Schönbrunn, Ernst ^a   Sebti, Said M ^a   Earp, H Shelton ^b   Mahajan, Nupam P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACK1 PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TNK2 PROTEIN, MOUSE; TYROSINE;

ANIMAL; ARTICLE; BREAST TUMOR; CELL MEMBRANE; CHEMISTRY; DISEASE COURSE; FEMALE; HUMAN; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CELL MEMBRANE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TYROSINE;

EID: 77954607192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009646     Document Type: Article

References (45)

1. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
2. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86.
3. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
4. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, et al. (1995) The protein kinase encoded by the Akt proto-oncogene is a target of the PDGFactivated phosphatidylinositol 3-kinase. Cell 81: 727-736.
5. Burgering BM, Coffer PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602.
6. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, et al. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279: 710-714.
7. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, et al. (1997) Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277: 567-570.
8. Dong LQ, Liu F (2005) PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab 289: E187-196.
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
10. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, et al. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 15: 6541-6551.
11. Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425.
12. Huang H, Tindall DJ (2007) Dynamic FoxO transcription factors. J Cell Sci 120: 2479-2487.
13. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
14. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, et al. (2006) The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A 103: 16296-16300.
15. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, et al. (2001) AKT1/ PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431-437.
16. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al. (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-6091.
17. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
18. Gami MS, Iser WB, Hanselman KB, Wolkow CA (2006) Activated AKT/PKB signaling in C. elegans uncouples temporally distinct outputs of DAF-2/insulinlike signaling. BMC Dev Biol 6: 45.
19. Bose S, Chandran S, Mirocha JM, Bose N (2006) The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19: 238-245.
20. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JF, et al. (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204: 93-100.
21. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, et al. (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788.
22. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, et al. (2008) PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol 140: 344-347.
23. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32.
24. Manser E, Leung T, Salihuddin H, Tan L, Lim L (1993) A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 363: 364-367.
25. Mahajan NP, Whang YE, Mohler JL, Earp HS (2005) Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 65: 10514-10523.
26. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, et al. (2007) Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A 104: 8438-8443.
27. Yokoyama N, Miller WT (2003) Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, authphosphorylation, and interaction with Hck. J Biol Chem 278: 47713-47723.
28. Galisteo ML, Yang Y, Urena J, Schlessinger J (2006) Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc Natl Acad Sci U S A 103: 9796-9801.
29. Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP (2010) Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate, manuscript in Press.
30. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, et al. (2005) Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A 102: 15901-15906.
31. Mahajan NP, Earp HS (2003) An SH2 domain-dependent, phosphotyrosineindependent interaction between Vav1 and the Mer receptor tyrosine kinase: a mechanism for localizing guanine nucleotide-exchange factor action. J Biol Chem 278: 42596-42603.
32. Kiyono M, Kato J, Kataoka T, Kaziro Y, Satoh T (2000) Stimulation of Ras guanine nucleotide exchange activity of Ras-GRF1/CDC25(Mm) upon tyrosine phosphorylation by the Cdc42-regulated kinase ACK1. J Biol Chem 275: 29788-29793.
33. Blanco-Aparicio C, Renner O, Leal JF, Carnero A (2007) PTEN, more than the AKT pathway. Carcinogenesis 28: 1379-1386.
34. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115.
35. Matsumoto J, Kaneda M, Tada M, Hamada J, Okushiba S, et al. (2002) Differential mechanisms of constitutive Akt/PKB activation and its influence on gene expression in pancreatic cancer cells. Jpn J Cancer Res 93: 1317-1326.
36. Sakurada A, Suzuki A, Sato M, Yamakawa H, Orikasa K, et al. (1997) Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 88: 1025-1028.
37. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
38. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
39. Shen F, Lin Q, Gu Y, Childress C, Yang W (2007) Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell 18: 732-742.
40. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D (2007) Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 9: 706-712.
41. Karathanassis D, Stahelin RV, Bravo J, Perisic O, Pacold CM, et al. (2002) Binding of the PX domain of p47(phox) to phosphatidylinositol 3,4-bisphosphate and phosphatidic acid is masked by an intramolecular interaction. Embo J 21: 5057-5068.
42. Santi SA, Lee H (2009) The Akt isoforms are present at distinct subcellular locations. Am J Physiol Cell Physiol.
43. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, et al. (2001) Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 276: 31858-31862.
44. Conus NM, Hannan KM, Cristiano BE, Hemmings BA, Pearson RB (2002) Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem 277: 38021-38028.
45. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482-7492.